Evidence map›Paper›PMID 36260162›Full record

Observational studyPediatric nephrology (Berlin, Germany)2023

Acute kidney injury during cisplatin therapy and associations with kidney outcomes 2 to 6 months post-cisplatin in children: a multi-centre, prospective observational study.

Kelly R McMahon, Asaf Lebel, Shahrad Rod Rassekh, Kirk R Schultz, Tom D Blydt-Hansen, Geoffrey D E Cuvelier, Cherry Mammen, Maury Pinsk, Bruce C Carleton, Ross T Tsuyuki and 10 more

Abstract readObservational StudyMulticenter Study
PubMed Publisher
In one paragraph

Observational study in Pediatric nephrology (Berlin, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 10 institutions in 1 country.

Kelly R McMahonDepartment of Pediatrics, Division of Nephrology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
Asaf LebelDepartment of Pediatrics, Division of Nephrology, The Hospital for Sick Children, Toronto, ON, Canada.
Shahrad Rod RassekhDepartment of Pediatrics, Division of Hematology/Oncology/Bone Marrow Transplantation, University of British Columbia, British Columbia Children's Hospital, Vancouver, BC, Canada.
Kirk R SchultzDepartment of Pediatrics, Division of Hematology/Oncology/Bone Marrow Transplantation, University of British Columbia, British Columbia Children's Hospital, Vancouver, BC, Canada.
Tom D Blydt-HansenDepartment of Pediatrics, Division of Pediatric Nephrology, University of British Columbia, British Columbia Children's Hospital, Vancouver, BC, Canada.
Geoffrey D E CuvelierResearch Institute in Oncology and Hematology, CancerCare Manitoba, Department of Pediatrics and Child Health, Division of Pediatric Oncology-Hematology-BMT, University of Manitoba, Winnipeg, MB, Canada.
Cherry MammenDepartment of Pediatrics, Division of Pediatric Nephrology, University of British Columbia, British Columbia Children's Hospital, Vancouver, BC, Canada.
Maury PinskDepartment of Pediatrics and Child Health, Section of Pediatric Nephrology, University of Manitoba, Winnipeg, MB, Canada.
Bruce C CarletonDepartment of Pediatrics, Division of Translational Therapeutics, BC Children's Hospital Research Institute, University of British Columbia, Vancouver, BC, Canada.
Ross T TsuyukiEpidemiology Coordinating and Research Centre, Departments of Pharmacology and Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
Colin J D RossFaculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada.
Louis HuynhFaculty of Health Sciences, Queen's University, Kingston, ON, Canada.
Mariya YordanovaFaculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada.
Frédérik Crépeau-HubertDepartment of Pediatrics, Division of Nephrology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
Stella WangChild Health Evaluative Sciences, Peter Gilgan Centre For Research and Learning, Room 11th floor, 11.9722, 686 Bay Street, Toronto, ON, M5G 0A4, Canada.
Ana PalijanDepartment of Pediatrics, Division of Nephrology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
Jasmine LeeChild Health Evaluative Sciences, Peter Gilgan Centre For Research and Learning, Room 11th floor, 11.9722, 686 Bay Street, Toronto, ON, M5G 0A4, Canada.
Debbie BoykoEpidemiology Coordinating and Research Centre, Departments of Pharmacology and Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
Michael ZappitelliChild Health Evaluative Sciences, Peter Gilgan Centre For Research and Learning, Room 11th floor, 11.9722, 686 Bay Street, Toronto, ON, M5G 0A4, Canada. michael.zappitelli@sickkids.ca.
Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Research Study Group
BC Children's Hospital · CAInstitute for Clinical Evaluative Sciences · CAUniversity of British Columbia · CAMcGill University Health Centre · CAUniversity of Alberta · CAUniversity of Manitoba · CAHospital for Sick Children · CAMcGill University · CAQueen's University · CAUniversité de Sherbrooke · CA

Funding

CIHR
6 · The paper itself

Abstract

backgroundFew studies describe acute kidney injury (AKI) burden during paediatric cisplatin therapy and post-cisplatin kidney outcomes. We determined risk factors for and rate of (1) AKI during cisplatin therapy, (2) chronic kidney disease (CKD) and hypertension 2-6 months post-cisplatin, and (3) whether AKI is associated with 2-6-month outcomes.

methodsThis prospective cohort study enrolled children (aged < 18 years at cancer diagnosis) treated with cisplatin from twelve Canadian hospitals. AKI during cisplatin therapy (primary exposure) was defined based on Kidney Disease: Improving Global Outcomes (KDIGO) serum creatinine criteria (≥ stage one). Severe electrolyte abnormalities (secondary exposure) included ≥ grade three hypophosphatemia, hypokalemia, or hypomagnesemia (National Cancer Institute Common Terminology Criteria for Adverse Events v4.0). CKD was albuminuria or decreased kidney function for age (KDIGO guidelines). Hypertension was defined based on the 2017 American Academy of Pediatrics guidelines.

resultsOf 159 children (median [interquartile range [IQR]] age: 6 [2-12] years), 73/159 (46%) participants developed AKI and 55/159 (35%) experienced severe electrolyte abnormalities during cisplatin therapy. At median [IQR] 90 [76-110] days post-cisplatin, 53/119 (45%) had CKD and 18/128 (14%) developed hypertension. In multivariable analyses, AKI was not associated with 2-6-month CKD or hypertension. Severe electrolyte abnormalities during cisplatin were associated with having 2-6-month CKD or hypertension (adjusted odds ratio (AdjOR) [95% CI]: 2.65 [1.04-6.74]). Having both AKI and severe electrolyte abnormalities was associated with 2-6-month hypertension (AdjOR [95% CI]: 3.64 [1.05-12.62]).

conclusionsSevere electrolyte abnormalities were associated with kidney outcomes. Cisplatin dose optimization to reduce toxicity and clear post-cisplatin kidney follow-up guidelines are needed. A higher resolution version of the Graphical abstract is available as Supplementary information.

Indexed as

Acute Kidney InjuryHypertensionRenal Insufficiency, ChronicCanadaChildChild, PreschoolCisplatinElectrolytesHumansKidneyProspective StudiesRetrospective StudiesRisk FactorsCisplatinElectrolytesAcute kidney injuryChronic kidney diseaseCisplatin nephrotoxicityEpidemiologyHypertensionPaediatric nephrology

Identifiers

PMID36260162
OpenAlexW4306773504

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.